FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000686231> ?p ?o ?g. }

• W2000686231 endingPage "103" @default.
• W2000686231 startingPage "99" @default.
• W2000686231 abstract "Only on the basis of the involvement of the vhl suppressor gene in the cases of renal cell carcinomas (RCC), the involvement of the signaling pathway between the pVHL and the hypoxia inducible factor 1 alpha (HIF-1α) has been evaluated because of the need to find new diagnostic and prognostic response to drugs markers. The overexpression of HIF-1α confers better prognosis in clear cell type RCC (ccRCC). Furthermore, HIF-1α regulates other genes, specifically that of the carbon anhydrase IX (CA-IX), whose overexpression is practically only one of the ccRCC and its determination is useful for this subtype. However, the involvement of the CA-IX has not been demonstrated in the prognosis or in the response to immunomodulators or antiangiogenics. Therefore, it is necessary to make a global evaluation of all this pathway: pVHL → HIF-1α → CA-IX, and even the analysis of other proteins and signaling pathways that also control the HIF-1α activity. In the latter case, the MAPK are critical in the HIF-1α activation, there being evidence on the experimental level of the control on its activity. Although the role of the MAPK in the phenomena of resistance to conventional chemotherapy and radiotherapy has been demonstrated, it has not been demonstrated in response to sorafenib, an important piece of information if we consider that it is an inhibitor of several protein kinases. Recently, it has been observed that the MAPK may be involved in the responses to different therapies, included those based on tyrosine kinase inhibitors. The confirmation of these data would suppose an explanation of the variation observed between patients who, with the same functional alteration of the vhl gene, have a different biological, clinical behavior and better selection of non-surgical therapies. Últimamente, basándose en la implicación del gen supresor vhl en los casos de carcinoma de células renales (CCR), se ha evaluado la implicación de la ruta de señalización entre pVHL y el Factor Inducible por Hipoxia 1 alfa (HIF-1α), ante la necesidad de encontrar nuevos marcadores diagnósticos, pronósticos y de respuesta a fármacos. La sobreexpresión de HIF-1α confiere mejor pronóstico en pacientes afectos de CCR de tipo células claras (ccRCC). Además HIF-1α regula otros genes, concretamente el de la anhidrasa carbónica IX (CA-IX), cuya sobreexpresión es prácticamente exclusiva de los ccRCC y su determinación útil para el diagnóstico de este subtipo. Sin embargo, no se ha demostrado la implicación de CA-IX ni en el pronóstico, ni en la respuesta a inmunomoduladores o antiangiogénicos. Ello hace necesario la evaluación global de toda esta ruta: pVHL → HIF-1α → CA-IX, e incluso el análisis de otras proteínas y vías de señalización que también controlan la actividad de HIF-1α. En este ultimo caso, las MAPK, son criticas en la activación de HIF-1α, existiendo evidencias a nivel experimental del control sobre su actividad, aunque no se ha establecido su papel clínico como biomarcador. Si bien está demostrado el papel de las MAPK en los fenómenos de resistencia a quimio y radioterapia convencional, no lo está en la respuesta a sorafenib, dato llamativo si tenemos en cuenta que es inhibidor de varias proteín quinasas. Recientemente se ha observado que las MAPK pueden estar implicadas en la respuesta a distintas terapias, incluidas las basadas en inhibidores de tirosin quinasa. La confirmación de estos datos, supondrá una explicación a la variación observada entre pacientes, que con una misma alteración funcional del gen vhl, presentan un distinto comportamiento biológico y clínico, y a una mejor selección de terapias no quirúrgicas." @default.
• W2000686231 created "2016-06-24" @default.
• W2000686231 creator A5024033912 @default.
• W2000686231 creator A5043846972 @default.
• W2000686231 creator A5062659757 @default.
• W2000686231 creator A5075562232 @default.
• W2000686231 creator A5080827207 @default.
• W2000686231 date "2012-02-01" @default.
• W2000686231 modified "2023-09-24" @default.
• W2000686231 title "Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma" @default.
• W2000686231 cites W1883934225 @default.
• W2000686231 cites W1968972540 @default.
• W2000686231 cites W1973460380 @default.
• W2000686231 cites W1987825597 @default.
• W2000686231 cites W1996675163 @default.
• W2000686231 cites W2000624133 @default.
• W2000686231 cites W2008836121 @default.
• W2000686231 cites W2011826559 @default.
• W2000686231 cites W2015846683 @default.
• W2000686231 cites W2024955968 @default.
• W2000686231 cites W2035763807 @default.
• W2000686231 cites W2038207337 @default.
• W2000686231 cites W2085049553 @default.
• W2000686231 cites W2086394732 @default.
• W2000686231 cites W2095968776 @default.
• W2000686231 cites W2105916091 @default.
• W2000686231 cites W2107942483 @default.
• W2000686231 cites W2118618934 @default.
• W2000686231 cites W2144099695 @default.
• W2000686231 cites W2144785546 @default.
• W2000686231 cites W2155784435 @default.
• W2000686231 cites W2157037524 @default.
• W2000686231 cites W2157120864 @default.
• W2000686231 cites W2158102364 @default.
• W2000686231 cites W2172170481 @default.
• W2000686231 cites W4205956911 @default.
• W2000686231 cites W4229566733 @default.
• W2000686231 cites W4236339397 @default.
• W2000686231 cites W4238530569 @default.
• W2000686231 cites W4245152726 @default.
• W2000686231 cites W4291518211 @default.
• W2000686231 doi "https://doi.org/10.1016/j.acuroe.2012.04.009" @default.
• W2000686231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21959062" @default.
• W2000686231 hasPublicationYear "2012" @default.
• W2000686231 type Work @default.
• W2000686231 sameAs 2000686231 @default.
• W2000686231 citedByCount "6" @default.
• W2000686231 countsByYear W20006862312015 @default.
• W2000686231 countsByYear W20006862312016 @default.
• W2000686231 countsByYear W20006862312022 @default.
• W2000686231 countsByYear W20006862312023 @default.
• W2000686231 crossrefType "journal-article" @default.
• W2000686231 hasAuthorship W2000686231A5024033912 @default.
• W2000686231 hasAuthorship W2000686231A5043846972 @default.
• W2000686231 hasAuthorship W2000686231A5062659757 @default.
• W2000686231 hasAuthorship W2000686231A5075562232 @default.
• W2000686231 hasAuthorship W2000686231A5080827207 @default.
• W2000686231 hasConcept C126322002 @default.
• W2000686231 hasConcept C184235292 @default.
• W2000686231 hasConcept C2777472916 @default.
• W2000686231 hasConcept C2778019345 @default.
• W2000686231 hasConcept C2778695046 @default.
• W2000686231 hasConcept C2781278892 @default.
• W2000686231 hasConcept C42362537 @default.
• W2000686231 hasConcept C502942594 @default.
• W2000686231 hasConcept C55493867 @default.
• W2000686231 hasConcept C57074206 @default.
• W2000686231 hasConcept C62112901 @default.
• W2000686231 hasConcept C62478195 @default.
• W2000686231 hasConcept C71924100 @default.
• W2000686231 hasConcept C86803240 @default.
• W2000686231 hasConcept C95444343 @default.
• W2000686231 hasConcept C97029542 @default.
• W2000686231 hasConceptScore W2000686231C126322002 @default.
• W2000686231 hasConceptScore W2000686231C184235292 @default.
• W2000686231 hasConceptScore W2000686231C2777472916 @default.
• W2000686231 hasConceptScore W2000686231C2778019345 @default.
• W2000686231 hasConceptScore W2000686231C2778695046 @default.
• W2000686231 hasConceptScore W2000686231C2781278892 @default.
• W2000686231 hasConceptScore W2000686231C42362537 @default.
• W2000686231 hasConceptScore W2000686231C502942594 @default.
• W2000686231 hasConceptScore W2000686231C55493867 @default.
• W2000686231 hasConceptScore W2000686231C57074206 @default.
• W2000686231 hasConceptScore W2000686231C62112901 @default.
• W2000686231 hasConceptScore W2000686231C62478195 @default.
• W2000686231 hasConceptScore W2000686231C71924100 @default.
• W2000686231 hasConceptScore W2000686231C86803240 @default.
• W2000686231 hasConceptScore W2000686231C95444343 @default.
• W2000686231 hasConceptScore W2000686231C97029542 @default.
• W2000686231 hasIssue "2" @default.
• W2000686231 hasLocation W20006862311 @default.
• W2000686231 hasOpenAccess W2000686231 @default.
• W2000686231 hasPrimaryLocation W20006862311 @default.
• W2000686231 hasRelatedWork W1976734851 @default.
• W2000686231 hasRelatedWork W2042017613 @default.
• W2000686231 hasRelatedWork W2144611693 @default.
• W2000686231 hasRelatedWork W2167849512 @default.
• W2000686231 hasRelatedWork W2350517500 @default.

• next